INTRODUCTION {#s1}
============

Renal cell carcinoma (RCC) has around 350,000 newly diagnosed cases every year and is one of the most common histologic types of kidney cancer. At the same time, the mortality of RCC is more than 140,000 per year worldwide \[[@R1], [@R2]\]. However, to date, the definite etiology of RCC is still not well defined. Several epidemiologic studies showed that the etiology of RCC is a complex interaction between environmental and multigenetic factors. Tobacco exposure \[[@R3]\], obesity \[[@R4]\] and hypertension \[[@R5]\] are accepted major risk factors for RCC. Recent molecular studies have reported that abnormal expression of VEGF contribute to tumorigenesis \[[@R6]\].

The VEGF gene is located on chromosome 6p21.3 and consists of 8 exons \[[@R7]\]. It plays a critical role in physiological and pathological angiogenesis which is a relatively early event in tumor development, progression and metastasis \[[@R8], [@R9]\]. Previous studies observed that functional single-nucleotide polymorphisms (SNPs) in either the regulatory or coding sequence of VEGF affects gene expression in various diseases including lung cancer \[[@R10]\], cardiovascular disease \[[@R11]\] and gastric cancer \[[@R12]\]. Some of VEGF SNPs, such as rs2010963 polymorphism (+405G/C, also named as -634G/C) in the 5'-untranslated region, rs3025039 polymorphism (+936C/T) in the 3'-UTR of the gene and rs699947 polymorphism (−2578C/A) in the promoter region have been suspected to correlate with RCC risk \[[@R13]--[@R17]\].

Recently, a series of case-control studies focusing on the associations between gene mutations (particularly SNPs) and the risk of RCC have been extensively studied \[[@R18]--[@R21]\]. However the results have been inconsistent. We conducted the present systematic review and meta-analysis to better understand the effects of VEGF rs2010963, rs3025039 and rs699947 polymorphisms on RCC susceptibility.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

A total of 550 articles were identified through a literature search in PubMed, ISI, Wangfang, Google Scholar and CNKI databases. Nine eligible studies were retrieved for detailed evaluation (Figure [1](#F1){ref-type="fig"}). The quality assessment was conducted using the Newcastle-Ottawa Scale (NOS) and all of studies got 6-7 points ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We included seven studies that described an association between rs2010963 polymorphism and RCC susceptibility including 2315 cases and 3552 controls. Seven studies described an association between rs3025039 polymorphism and RCC susceptibility, including 1636 cases and 2711 controls. For rs699947 polymorphism, six studies were studied including a total of 1588 cases and 2470 controls. The genotypes of seven studies were detected by PCR-RFLP (restriction fragment length polymorphism) and two by TaqMan assay (Table [1](#T1){ref-type="table"}).

![Flow diagram of study identification](oncotarget-08-50061-g001){#F1}

###### Characteristics of studies on VEGF polymorphisms and RCC risk included in the meta-analysis

  First author   Year   Population   Genotype method   Case   Control   Genotype distribution   P HWE                           
  -------------- ------ ------------ ----------------- ------ --------- ----------------------- ------- ----- ----- ----- ----- ----------
  rs2010963                                                             GG                      GC      CC    GG    GC    CC    
  Bruyère        2010   France       PCR-RFLP          48     198       15                      25      8     86    92    20    0.522
  Sáenz-López    2013   Spain        TaqMan            214    279       101                     93      20    129   118   32    0.528
  Chao           2014   China        PCR-RFLP          824    983       287                     391     146   410   429   144   0.068
  Lu             2015   China        PCR-RFLP          412    824       139                     194     79    299   377   148   0.127
  Xian           2015   China        PCR-RFLP          266    532       30                      132     104   49    256   227   0.053
  Shen           2015   China        PCR-RFLP          360    360       121                     170     69    134   163   63    0.273
  Yang           2015   Taiwan       TaqMan            191    376       62                      90      39    136   173   67    0.355
  rs3025039                                                             CC                      CT      TT    CC    CT    TT    
  Abe            2002   Japanese     PCR-RFLP          145    145       97                      41      7     90    52    3     0.146
  Bruyère        2010   France       PCR-RFLP          47     196       29                      17      1     141   53    2     0.218
  Sáenz-López    2013   Spain        TaqMan            215    280       156                     57      2     200   73    7     0.912
  Lu             2015   China        PCR-RFLP          412    824       262                     91      59    554   166   104   \<0.01\*
  Xian           2015   China        PCR-RFLP          266    532       70                      127     69    196   236   100   0.056
  Shen           2015   China        PCR-RFLP          360    359       224                     81      55    240   73    46    \<0.01\*
  Yang           2015   Taiwan       TaqMan            191    375       122                     59      10    232   121   22    0.247
  rs699947                                                              CC                      CA      AA    CC    CA    AA    
  Ajaz           2011   Pakistan     PCR-RFLP          143    106       30                      81      32    44    41    21    0.053
  Sáenz-López    2013   Spain        TaqMan            216    272       54                      114     48    77    142   53    0.388
  Lu             2015   China        PCR-RFLP          412    824       171                     174     67    397   332   95    0.047\*
  Xian           2015   China        PCR-RFLP          266    532       99                      119     48    243   225   64    0.29
  Shen           2015   China        PCR-RFLP          360    360       150                     149     61    178   141   41    0.11
  Yang           2015   Taiwan       TaqMan            191    376       106                     75      10    200   153   23    0.377

\* represent the genotype distribution of control sample was not meeting Hardy-Weinberg equilibrium.

Association between rs2010963 polymorphism and RCC risk {#s2_2}
-------------------------------------------------------

The data of seven studies was available to investigate the association between rs2010963 poly-morphisms and RCC risk. The meta-analysis found a significant association between rs2010963 polymorphism and RCC susceptibility \[GG vs. GC+CC (OR = 0.85; 95%CI = 0.75-0.97; *P* = 0.01; I^2^ = 11%); GG vs. GC (OR = 0.86; 95%CI = 0.76-0.97; *P* =0.01; I^2^ = 0%)\] (Table [2](#T2){ref-type="table"}; Figure [2A](#F2){ref-type="fig"}). Subgroup analysis found a similar decreased risk for RCC in the Asian population with a GG genotype \[GG vs. GC+CC (OR = 0.84; 95%CI = 0.74-0.96; *P* = 0.01; I^2^ = 8%); GG vs. GC (OR = 0.85; 95%CI = 0.75-0.97; *P* =0.02; I^2^ = 0%)\] (Table [2](#T2){ref-type="table"}; Figure [2A](#F2){ref-type="fig"}).

###### Summary ORs and 95%CI of VEGF polymorphisms and RCC risk

  rs2010963       N   G vs. C             GG vs. CC   GG vs. GC   GC vs. CC          GG+GC vs. CC   GG vs. GC+CC                                                                                                                              
  --------------- --- ------------------- ----------- ----------- ------------------ -------------- -------------- ------------------ ------ ---- ------------------ ------ ---- ------------------ -------- ---- ------------------ -------- ----
  Total           7   0.92 (0.82, 1.02)   0.10        39          0.85(0.69, 1.04)   0.11           30             0.86(0.76,0.97)    0.01   0    0.97(0.84,1.12)    0.72   0    0.92(0.80,1.06)    0.24     0    0.85(0.75,0.97)    0.01     11
  Caucasian       2   0.88 (0.56, 1.39)   0.58        67          0.80(0.29, 2.22)   0.66           68             0.89(0.61, 1.29)   0.53   13   1.02(0.58, 1.82)   0.93   15   1.00(0.61, 1.64)   0.99     54   0.85(0.50, 1.44)   0.54     52
  Asian           5   0.91(0.82, 1.02)    0.09        39          0.83(0.68, 1.01)   0.07           23             0.85(0.75, 0.97)   0.02   0    0.97(0.83, 1.12)   0.67   0    0.91(0.79, 1.05)   0.22     0    0.84(0.74, 0.96)   0.01     8
  rs3025039           C vs. T             CC vs. TT   CC vs. CT   CT vs. TT          CC+CT vs. TT   CC vs. CT+TT                                                                                                                              
  Total           7   0.88 (0.76, 1.01)   0.06        39          0.75(0.57, 0.99)   0.04           25             0.90(0.76, 1.06)   0.21   24   0.89(0.71, 1.11)   0.29   0    0.79(0.65, 0.97)   0.02     0    0.87(0.73, 1.04)   0.13     40
  Caucasian       2   0.91 (0.56, 1.48)   0.71        53          1.33(0.22, 8.19)   0.76           40             0.87(0.58, 1.30)   0.50   18   1.77(0.46, 6.81)   0.41   0    1.46(0.28, 7.64)   0.66     30   0.88(0.54, 1.43)   0.60     42
  Asian           5   0.86(0.74, 1.00)    0.05        43          0.73(0.56, 0.94)   0.02           22             0.91(0.73, 1.12)   0.36   40   0.87(0.69, 1.09)   0.22   0    0.78(0.64, 0.96)   0.02     0    0.87(0.70, 1.07)   0.18     51
  HWE-yes         5   0.91(0.72, 1.15)    0.43        59          0.76(0.42, 1.37)   0.36           41             0.92(0.70, 1.21)   0.55   48   0.83(0.58, 1.19)   0.31   5    0.79(0.51, 1.22)   0.28     20   0.90(0.67, 1.21)   0.47     59
  HWE-no          2   0.85(0.73, 0.99)    0.03        0           0.81(0.62, 1.07)   0.13           0              0.87(0.69, 1.09)   0.22   0    0.95(0.69, 1.31)   0.76   0    0.84(0.65, 1.10)   0.21     0    0.84(0.69, 1.02)   0.07     0
  Asian HWE-yes   3   0.91(0.66, 1.25)    0.55        71          0.66(0.37, 1.15)   0.14           41             0.97(0.64, 1.47)   0.88   69   0.79(0.56, 1.09)   0.15   0    0.71(0.50, 1.00)   0.05     6    0.92(0.59, 1.43)   0.71     75
  rs699947            A vs. C             AA vs. CC   AA vs. AC   AC vs. CC          AA+AC vs. CC   AA vs. AC+CC                                                                                                                              
  Total           6   1.25(1.11, 1.42)    \<0.01      38          1.61(1.32, 1.97)   \<0.01         0              1.23(1.02, 1.50)   0.03   0    1.27(1.03, 1.57)   0.03   52   1.33(1.09, 1.63)   \<0.01   55   1.39(1.16, 1.67)   \<0.01   0
  Caucasian       2   1.31(0.94, 1.84)    0.12        58          1.60(0.95, 2.71)   0.08           31             1.00(0.68, 1.46)   0.99   0    1.78(0.72, 4.41)   0.21   84   1.74(0.78, 3.85)   0.17     81   1.18(0.82, 1.68)   0.38     0
  Asian           4   1.24(1.07, 1.44)    \<0.01      47          1.61(1.26, 2.06)   \<0.01         12             1.33(1.06, 1.68)   0.01   0    1.18(1.02, 1.38)   0.03   0    1.26(1.06, 1.50)   \<0.01   30   1.48(1.20, 1.83)   \<0.01   0
  HWE-yes         5   1.24(1.06, 1.46)    \<0.01      50          1.58(1.21, 2.07)   \<0.01         18             1.19(0.95, 1.50)   0.14   0    1.30(0.98, 1.72)   0.07   62   1.35(1.03, 1.77)   0.03     64   1.36(1.09, 1.69)   \<0.01   0
  Asian HWE-yes   3   1.21(0.96, 1.52)    0.10        64          1.54(1.04, 2.30)   0.03           41             1.33(0.99, 1.78)   0.06   0    1.16(0.95, 1.42)   0.14   9    1.23(0.94, 1.59)   0.13     52   1.46(1.08, 1.97)   0.01     13
  Total           6   1.25(1.11, 1.42)    \<0.01      38          1.61(1.32, 1.97)   \<0.01         0              1.23(1.02, 1.50)   0.03   0    1.27(1.03, 1.57)   0.03   52   1.33(1.09, 1.63)   \<0.01   55   1.39(1.16, 1.67)   \<0.01   0

![The association of rs2010963 polymorphism with RCC susceptibility in the GG vs. GC+CC model\
**(A)** ORs and 95%CIs. **(B)** Sensitivity analysis. **(C)** Publication bias.](oncotarget-08-50061-g002){#F2}

Sensitivity analyses revealed that the results of the pooled ORs were stable (Figure [2B](#F2){ref-type="fig"} for the dominant model). No evidence of publication bias was observed in the Begg\'s rank correlation method and Egger\'s weighted regression method \[G vs. C (Begg\'s test: *P* = 1.000; Egger\'s test: *P* = 0.723); GG+GC vs. CC (Begg\'s test: *P* = 0.764; Egger\'s test: *P* = 0.888); GG vs. GC+CC (Begg\'s test: *P* = 0.764; Egger\'s test: *P* = 0.437); GG vs. CC (Begg\'s test: *P* = 0.548; Egger\'s test: *P* = 0.444); GG vs. GC (Begg\'s test: *P* = 0.548; Egger\'s test: *P* = 0.417);GC vs. CC (Begg\'s test: *P* = 0.548; Egger\'s test: *P* = 0.825)\] (Figure [2C](#F2){ref-type="fig"} for the dominant model).

Association between rs3025039 polymorphism and RCC risk {#s2_3}
-------------------------------------------------------

Seven studies were available to investigate the association between rs3025039 polymorphisms and RCC risk. The meta-analysis found a significant association between rs3025039 polymorphism and RCC susceptibility \[CC+CT vs. TT (OR = 0.79; 95%CI = 0.65-0.97; *P* = 0.02; I^2^ = 0%); CC vs. TT (OR = 0.75; 95%CI = 0.57-0.99; *P* =0.04; I^2^ = 25%)\] (Table [2](#T2){ref-type="table"}; Figure [3A](#F3){ref-type="fig"}). Subgroup analysis found a similar decreased risk for the Asian population with a C allele \[C vs. T (OR = 0.86; 95%CI = 0.74-1.00; *P* =0.05; I^2^ = 43%); CC+CT vs. TT (OR = 0.78; 95%CI = 0.64-0.96; *P* =0.02; I^2^ = 0%); CC vs. TT (OR = 0.73; 95%CI = 0.56-0.94; *P* =0.02; I^2^ = 22%)\] (Table [2](#T2){ref-type="table"}; Figure [3A](#F3){ref-type="fig"}). Because the genotype distribution of control samples reported by Lu et al. and Shen et al. did not meet the Hardy-Weinberg equilibrium, we conducted the subgroup analysis excluding them. The subgroup analysis detected an association between the C allele of rs3025039 polymorphism and RCC susceptibility in the Asian population \[CC+CT vs. TT (OR = 0.71; 95%CI = 0.50-1.00; *P* =0.05; I^2^ = 6%)\] (Table [2](#T2){ref-type="table"}).

![The association of rs3025039 polymorphism with RCC susceptibility in the CC+CT vs. TT model\
**(A)** ORs and 95%CIs. **(B)** Sensitivity analysis. **(C)** Publication bias.](oncotarget-08-50061-g003){#F3}

Sensitivity analyses revealed that the results of the pooled ORs were stable (Figure [3B](#F3){ref-type="fig"} for the recessive model). No evidence of publication bias was observed in the Begg\'s rank correlation method and Egger\'s weighted regression method \[C vs. T (Begg\'s test: *P* = 1.000; Egger\'s test: *P* = 0.409); CC+CT vs. TT (Begg\'s test: *P* = 0.764; Egger\'s test: *P* = 0.674); CC vs. CT+TT (Begg\'s test: *P* = 0.764; Egger\'s test: *P* = 0.727); CC vs. TT (Begg\'s test: *P* = 0.764; Egger\'s test: *P* = 0.673); CC vs. CT (Begg\'s test: *P* = 0.548; Egger\'s test: *P* = 0.793); CT vs. TT (Begg\'s test: *P* = 0.764; Egger\'s test: *P* = 0.874)\] (Figure [3C](#F3){ref-type="fig"} for the recessive model).

Association between rs699947 polymorphism and RCC risk {#s2_4}
------------------------------------------------------

Six studies were available to investigate the association between rs699947 polymorphisms and RCC risk. The meta-analysis found a significant association between rs699947 polymorphism and RCC susceptibility \[A vs. C (OR = 1.25; 95%CI = 1.11-1.42; *P* = 0.0004; I^2^ = 38%); AA+AC vs. CC (OR = 1.33; 95%CI = 1.09-1.63; *P* = 0.006; I^2^ = 55%); AA vs. AC+CC (OR = 1.39; 95%CI = 1.16-1.67; *P* = 0.0004; I^2^ = 0%); AA vs. CC (OR = 1.61; 95%CI = 1.32-1.97; *P* \<0.00001; I^2^ = 0%); AA vs. AC (OR = 1.23; 95%CI = 1.02-1.50; *P* =0.03; I^2^ = 0%);AC vs. CC (OR = 1.27; 95%CI = 1.23-1.99; *P* = 0.03; I^2^ = 52%)\] (Table [2](#T2){ref-type="table"}; Figure [4A](#F4){ref-type="fig"}).

![The association of rs699947 polymorphism with RCC susceptibility in the A allele vs. C allele model\
**(A)** ORs and 95%CIs. **(B)** Sensitivity analysis. **(C)** Publication bias.](oncotarget-08-50061-g004){#F4}

Subgroup analysis found a similar increased risk in the Asian population with an A allele \[A vs. C (OR = 1.24; 95%CI = 1.07-1.44; *P*\<0.01; I^2^ = 47%); AA+AC vs. CC (OR = 1.26; 95%CI = 1.06-1.50; *P*\<0.01; I^2^ = 30%); AA vs. AC+CC (OR = 1.48; 95%CI = 1.20-1.83; *P*\<0.01; I^2^ = 0%); AA vs. CC (OR = 1.61; 95%CI = 1.26-2.06; *P*\<0.00001; I^2^ = 0%); AA vs. AC (OR = 1.33; 95%CI = 1.06-1.68; *P* =0.01; I^2^ = 0%);AC vs. CC (OR = 1.18; 95%CI = 1.02-1.38; *P* = 0.03; I^2^ = 0%)\] (Table [2](#T2){ref-type="table"}; Figure [4A](#F4){ref-type="fig"}). Because the genotype distribution of control samples reported by Lu et al. did not meet the Hardy-Weinberg equilibrium, we conducted the subgroup analysis excluding it. This subgroup analysis detected a significant association between rs699947 polymorphism and RCC \[A vs. C (OR = 1.24; 95%CI = 1.06-1.46; *P*\<0.01; I^2^ = 50%); AA+AC vs. CC (OR = 1.35; 95%CI = 1.03-1.77; *P*=0.03; I^2^ = 64%); AA vs. AC+CC (OR = 1.36; 95%CI = 1.09-1.69; *P*\<0.01; I^2^ = 0%); AA vs. CC (OR = 1.58; 95%CI = 1.21-2.07; *P*\<0.01; I^2^ = 18%)\], even in the Asian population \[AA vs. AC+CC (OR = 1.46; 95%CI = 1.08-1.97; *P*=0.01; I^2^ = 13%); AA vs. CC (OR = 1.54; 95%CI = 1.04-2.30; *P*=0.03; I^2^ = 41%)\] (Table [2](#T2){ref-type="table"}).

Sensitivity analyses revealed that the results of the pooled ORs were stable (Figure [4B](#F4){ref-type="fig"} for the allelic model). No evidence of publication bias was observed in the Begg\'s rank correlation method and Egger\'s weighted regression method \[A vs. C (Begg\'s test: *P* = 1.000; Egger\'s test: *P* = 0.825); AA+AC vs. CC (Begg\'s test: *P* = 0.707; Egger\'s test: *P* = 0.469); AA vs. AC+CC (Begg\'s test: *P* = 0.133; Egger\'s test: *P* = 0.057); AA vs. CC (Begg\'s test: *P* = 0.707; Egger\'s test: *P* = 0.454); AA vs. AC (Begg\'s test: *P* = 0.133; Egger\'s test: *P* = 0.040);AC vs. CC (Begg\'s test: *P* = 0.707; Egger\'s test: *P* = 0.254)\] (Figure [4C](#F4){ref-type="fig"} for the allelic model).

DISCUSSION {#s3}
==========

Angiogenesis, the generation of new capillary from basal vessels under both physiological and pathological conditions, is a relatively early event in tumor growth and metastasis \[[@R8], [@R22]\]. VEGF, a common pro-angiogenic growth factor, is associated with angiogenesis in multiple kinds of tumor including breast \[[@R23]\], colorectal \[[@R24]\] and kidney cancer \[[@R6]\]. A previous meta-analysis conducted by Gong et al. reported that VEGF gene rs699947 polymorphism and rs3025039 polymorphism correlates with an increased susceptibility of RCC \[[@R25]\]. However, this meta-analysis mistakenly treated VEGF gene SNP +405G/C and -634G/C, two aliases of rs2010963, as different polymorphisms. Furthermore, this study did not reveal the influence and heterogeneity from the including studies which were diverse in ethnicity. Another study by Yang et al stated that there was no significant association between VEGF gene polymorphisms and RCC risk \[[@R26]\].

In the present study, the pooled analysis of seven studies revealed that GC and GC+CC genotypes of rs2010963 were significantly associated with an increased risk of RCC when compared with the GG genotype. In the subgroup analysis, similar results were observed in the Asian population. If the fixed effects model was used, the C-allele of rs2010963 polymorphism was also found to increase RCC susceptibility. Besides intimate connection with the occurrence of RCC, the VEGF rs2010963 polymorphism may also be associated with more invasive biological behavior and malignancy. A previous study showed that the frequency of the CC genotype of VEGF rs2010963 polymorphism was significantly higher in advanced clinical TNM patients with a renal tumor size of more than 4 cm \[[@R15]\]. In advanced RCC patients receiving sunitinib therapy, the carrier C-allele of rs2010963 polymorphism is significantly related with a worse progression free survival and overall survival \[[@R27]\]. These findings support the hypothesis that VEGF rs2010963 polymorphism might play a role in RCC, and the C-allele might be a risk factor for RCC.

This meta-analysis also investigated the association between VEGF rs3025039 polymorphism and susceptibility to RCC. In our analysis, the results revealed that the CC genotype and CC+CT genotype were significantly associated with a decreased risk for RCC when compared with the TT genotype. However, in the subgroup analyses that excluded two studies not meeting the HWE there was no significant association. When including the studies that met the HWE status and were carried out in the Asian population, the CC+CT genotype of rs3025039 polymorphism showed a marginal significant correlation with a decreased risk of RCC when compared to those carrying the TT genotypes. In 2016, Gong et al conducted a meta-analysis and found that most genetic models and alleles displayed high susceptibility to RCC when regarding the VEGF rs3025039 polymorphism \[[@R25]\]. However, their study did not take in to account the heterogeneity of the included studies which were diverse in ethnicity or did not meet the HWE. We conducted a more comprehensive and cautious meta-analysis including seven eligible studies and only using random-effects models. Moreover, our subgroup analysis was based on HWE status and the Asian population. As a result we found a suspicious association which was different from the study by Gong et al. Therefore, the association between VEGF rs3025039 polymorphism and RCC needs to be validated further.

For VEGF rs699947 polymorphism, we also conducted an updated meta-analysis including six eligible studies. The pooled estimate found an increased risk for RCC in the A-carrier genotypes of VEGF rs699947 polymorphism. Our results confirmed the findings of two previous meta-analyses \[[@R25], [@R28]\]. Furthermore, subgroup analysis found that the AA genotype of rs699947 polymorphism was associated with an increased RCC susceptibility in the Asian population when compared with those carrying the CC or AC+CC genotype. Our findings indicate that the VEGF GG genotype of rs2010963 polymorphism decreased RCC susceptibility, especially in the Asian population. Moreover, the TT genotype of rs3025039 and AA genotype of rs699947 polymorphism were associated with an increased RCC susceptibility. For ethnicity variation, the possible reason may be most of our included studies were conducted in Asian and small sample size of studies conducted in Caucasian could lead to the discrepancy. When tested by sensitivity analysis, Begg\'s rank correlation method and Egger\'s weighted regression method, the results from the three SNP in VEGF did not identify any significant heterogeneity and/or publication bias.

This meta-analysis has several limitations. First, the number of studies and the sample size of the three VEGF polymorphisms were relatively small. As the individual information about the genotypes of the three VEGF polymorphisms was not sufficient, more clinical trials with larger sample size are required to address this issue. Second, only published studies were used for analysis in this study. Therefore, there might be publication bias even through tested by Begg\'s and Egger\'s method. Third, in this meta-analysis heterogeneity was detected, among the studies, which could influence the results. While the random-effects model would provide more conservative estimates with wider confidence intervals, we only used the random-effects model to calculate the pooled OR \[[@R29]\]. Even so, potential heterogeneity attributed by differences in ethnicity, design of the study, genotyping method, and limited sample size might not be discovered. Finally, because of insufficient individual participant data, the relationship between the haplotype of multiple VEGF polymorphisms, gene-gene and gene-environment interactions could not be estimated. If detailed information would have been available, this meta-analysis could offer more convincing evidence.

In conclusion, our meta-analysis suggests that three SNP (rs2010963, rs3025039 and rs699947) in VEGF are associated with RCC susceptibility especially in the Asian population. These SNPs in VEGF may be biomarkers for clinical evaluation. Nevertheless, additional well-designed studies including larger sample size and different ethnic groups are needed for re-evaluation of these associations.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

PubMed, Institute for Scientific Information (ISI), Wangfang, Google Scholar, and Chinese National Knowledge Infrastructure (CNKI) databases were searched for all articles describing an association between the VEGF polymorphisms and RCC risk up to November 2016. The key words used were "VEGF", "renal cancer/renal cell carcinoma", and "polymorphism/variant". The electronic search was supplemented by checking reference lists. All of the original studies had to meet the following criteria: (1) case-control design; (2) evaluate the association between the VEGF polymorphisms and RCC risk; (3) provide sufficient data for estimating an odds ratio (OR) with a 95% confidence interval (95% CI).

Data extraction {#s4_2}
---------------

Two of the authors extracted all data independently following the selection criteria. The following details were collected from each study: first author\'s name, publication year, country of study, ethnicity, number of cases and controls, genotyping method, and OR.

Quality assessment {#s4_3}
------------------

The methodological quality of each study was assessed by the Newcastle-Ottawa Scale (NOS), which uses total NOS scores (range from 0 to 9) to judge the quality of all included studies. Studies with seven or more points were considered to be of high quality.

Statistical analysis {#s4_4}
--------------------

The OR with 95%CI was used to assess the association between the VEGF polymorphisms and RCC based on the genotype frequencies in cases and controls. For each VEGF polymorphism, the meta-analysis examined the genetic susceptibility in 5 genetic models, including allelic, homozygote, heterozygote, dominant model, and recessive model. The heterogeneity among the studies was checked by using the I^2^ value. The pooled OR was calculated for each study using only the random-effects model, considering the random-effects model is more conservative and will provide better estimates with wider confidence intervals \[[@R29]\]. Subgroup analyses were conducted based on the classification of the population and HWE status. Sensitivity analyses were conducted to identify the influence from single studies to the pooled estimate. Publication bias was assessed by Egger\'s linear regression \[[@R30]\] and Begg\'s funnel plots \[[@R31]\]. Quantitative synthesis analysis was performed using RevMan 5.2 software (Cochrane IMS) and STATA version 12.0 (Stata Corporation, College Station, TX, USA).
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